{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:46:17Z","timestamp":1770511577763,"version":"3.49.0"},"reference-count":36,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.5551\/jat.65870","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:08:27Z","timestamp":1758146907000},"page":"216-227","source":"Crossref","is-referenced-by-count":0,"title":["Calculated Excess-Triglyceride Based on the Friedewald Formula is a Possible Surrogate Marker for the Production of Large Very-Low Density Lipoprotein, A Post-Hoc Analysis of the PROUD48 Study"],"prefix":"10.5551","volume":"33","author":[{"given":"Tsutomu","family":"Hirano","sequence":"first","affiliation":[{"name":"Diabetes Center, Ebina General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Endocrinology, Kanazawa Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Solis Sapporo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hiramitsu","sequence":"additional","affiliation":[{"name":"Hiramitsu Heart Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Okada","sequence":"additional","affiliation":[{"name":"Keiyukai Yoshida Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Social and Environmental Medicine, Kanazawa Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tan CE, Foster L, Caslake MJ, Bedford D, Watson TD, McConnell M, Packard CJ, Shepherd J. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. Arterioscler Thromb Vasc Biol, 1995; 15: 1839-1848","DOI":"10.1161\/01.ATV.15.11.1839"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, H\u00e4kkinen A, Olofsson SO, Yki-J\u00e4rvinen H, Bor\u00e9n J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia, 2006; 49: 755-765","DOI":"10.1007\/s00125-005-0125-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia, 2003; 46: 733-749","DOI":"10.1007\/s00125-003-1111-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, Packard CJ, Caslake MJ. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis, 2004; 176: 49-56","DOI":"10.1016\/j.atherosclerosis.2004.04.022"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Adiels M, Bor\u00e9n J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol, 2005; 25: 1697-1703","DOI":"10.1161\/01.ATV.0000172689.53992.25"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokg\u00f6zo\u011flu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J, 2021; 42: 4791-4806","DOI":"10.1093\/eurheartj\/ehab551"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol, 1997; 17: 3542-3556","DOI":"10.1161\/01.ATV.17.12.3542"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Milosavljevic D, Griglio S, Le Naour G, Chapman MJ. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis, 2001; 155: 251-260","DOI":"10.1016\/S0021-9150(00)00634-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Hirano T. Excess Triglycerides in Very Low-Density Lipoprotein (VLDL) Estimated from VLDL-Cholesterol could be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with Type 2 Diabetes. J Atheroscler Thromb, 2025; 32: 253-264","DOI":"10.5551\/jat.65164"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) M\u00e4nnist\u00f6 VT, Simonen M, Soininen P, Tiainen M, Kangas AJ, Kaminska D, Venesmaa S, K\u00e4kel\u00e4 P, K\u00e4rj\u00e4 V, Gylling H, Ala-Korpela M, Pihlajam\u00e4ki J. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res, 2014; 55: 2676-2684","DOI":"10.1194\/jlr.P054387"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S, Sakurai M. The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study). Front Cardiovasc Med, 2023; 10: 1094100","DOI":"10.3389\/fcvm.2023.1094100"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest, 1984; 74: 82-89","DOI":"10.1172\/JCI111422"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Wong AT, Chan DC, Ooi EM, Ng TW, Watts GF, Barrett PH. Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. Clin Sci (Lond), 2013; 125: 45-51","DOI":"10.1042\/CS20120587"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ferchaud-Roucher V, Zair Y, Aguesse A, Krempf M, Ouguerram K. Omega 3 Improves Both apoB100-containing Lipoprotein Turnover and their Sphingolipid Profile in Hypertriglyceridemia. J Clin Endocrinol Metab, 2020; 105: dgaa459","DOI":"10.1210\/clinem\/dgaa459"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ouguerram K, Maugeais C, Gardette J, Magot T, Krempf M. Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects. Br J Nutr, 2006; 96: 100-106","DOI":"10.1079\/BJN20061806"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes, 2003; 52: 803-811","DOI":"10.2337\/diabetes.52.3.803"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Millar JS, Duffy D, Gadi R, Bloedon LT, Dunbar RL, Wolfe ML, Movva R, Shah A, Fuki IV, McCoy M, Harris CJ, Wang MD, Howey DC, Rader DJ. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2009; 29: 140-146","DOI":"10.1161\/ATVBAHA.108.171223"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein S. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab, 2010; 95: 2727-2735","DOI":"10.1210\/jc.2009-2622"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res, 2004; 45: 174-185","DOI":"10.1194\/jlr.M300309-JLR200"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Shepherd J, Packard CJ, Stewart JM, Atmeh RF, Clark RS, Boag DE, Carr K, Lorimer AR, Ballantyne D, Morgan HG, et al. Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest, 1984; 74: 2164-2177","DOI":"10.1172\/JCI111643"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Masuda D, Sakai N, Sugimoto T, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M, Ishigami M, Masuda Y, Matsuyama A, Komuro I, Yamashita S. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. J Atheroscler Thromb, 2011; 18: 1062-1070","DOI":"10.5551\/jat.10470"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA, 2013; 310: 2061-2068","DOI":"10.1001\/jama.2013.280532"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hanada H, Mugii S, Okubo M, Maeda I, Kuwayama K, Hidaka Y, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Yuasa-Kawase M, Nakatani K, Tsubakio-Yamamoto K, Masuda D, Ohama T, Matsuyama A, Ishigami M, Nishida M, Komuro I, Yamashita S. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. Clin Chim Acta, 2012; 413: 160-165","DOI":"10.1016\/j.cca.2011.09.013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Okazaki M, Yamashita S. Recent Advances in Analytical Methods on Lipoprotein Subclasses: Calculation of Particle Numbers from Lipid Levels by Gel Permeation HPLC Using \u201cSpherical Particle Model\u201d. J Oleo Sci, 2016; 65: 265-282","DOI":"10.5650\/jos.ess16020"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hiukka A, Fruchart-Najib J, Leinonen E, Hilden H, Fruchart JC, Taskinen MR. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia, 2005; 48: 1207-1215","DOI":"10.1007\/s00125-005-1753-z"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Bor\u00e9n J, Watts GF, Adiels M, S\u00f6derlund S, Chan DC, Hakkarainen A, Lundbom N, Matikainen N, Kahri J, Verg\u00e8s B, Barrett PH, Taskinen MR. Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study. Arterioscler Thromb Vasc Biol, 2015; 35: 2218-2224","DOI":"10.1161\/ATVBAHA.115.305614"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagn\u00e9 C, Couture P. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism, 2008; 57: 246-254","DOI":"10.1016\/j.metabol.2007.09.008"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Adiels M, Matikainen N, Westerbacka J, S\u00f6derlund S, Larsson T, Olofsson SO, Bor\u00e9n J, Taskinen MR. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis, 2012; 222: 222-228","DOI":"10.1016\/j.atherosclerosis.2012.02.001"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest, 2004; 113: 1277-1287","DOI":"10.1172\/JCI19197"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Adiels, M.,C. Packard, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka,B. Wennberg, S-O. Olofsson, M-R. Taskinen, and J. Bor\u00e9n. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res, 2005; 46: 58-67","DOI":"10.1194\/jlr.M400108-JLR200"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis, 2008; 40: 194-199","DOI":"10.1016\/j.dld.2007.10.003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, Grzywacz K, Delvin E, Peretti N, Levy E. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. J Nutr Biochem, 2018; 58: 28-36","DOI":"10.1016\/j.jnutbio.2018.03.025"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol, 2008; 42: 413-418","DOI":"10.1097\/MCG.0b013e31815591aa"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Oscarsson J, \u00d6nnerhag K, Ris\u00e9rus U, Sund\u00e9n M, Johansson L, Jansson PA, Moris L, Nilsson PM, Eriksson JW, Lind L. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. J Clin Lipidol, 2018; 12: 1390-1403.e4","DOI":"10.1016\/j.jacl.2018.08.003"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Nilsson G, Shamburek RD, Vetrovec GW, Warnick GR, Remaley AT. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem, 2010; 56: 977-986","DOI":"10.1373\/clinchem.2009.142810"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/2\/33_65870\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:59:42Z","timestamp":1770436782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/2\/33_65870\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65870","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"article-number":"65870"}}